background
viral
pathogen
commonli
report
previous
estim
communityacquir
pneumonia
cap
patient
howev
real
role
viru
still
controversi
method
consecut
adult
patient
cap
april
decemb
prospect
enrol
fourfold
greater
increas
iggtitr
respiratori
virus
pair
sera
test
mean
hemagglutin
inhibit
assay
indirect
immunofluoresc
swab
sampl
test
cell
cultur
nucleic
amplif
test
viral
etiolog
consid
definit
least
one
test
posit
result
viral
etiolog
establish
fiftytwo
cap
patient
twentytwo
influenza
like
ill
patient
none
volunt
control
fortyseven
cap
patient
infect
singl
viru
influenza
viru
influenza
b
parainfluenza
viru
type
adenoviru
human
rhinoviru
coronaviru
five
case
two
three
virus
coinfect
fever
fatigu
purul
sputum
common
symptom
viral
pneumonia
patient
multivari
analysi
myalgia
includ
model
pneumonia
associ
influenza
infect
model
influenza
infect
found
independ
associ
sever
diseas
score
variabl
includ
age
year
sex
current
smoke
statu
sick
contact
febril
patient
number
comorbid
presenc
influenza
infect
presenc
piv
infect
p
ci
conclus
respiratori
viru
bystand
pathogen
pneumonia
common
caus
cap
china
pneumonia
rank
fifth
among
caus
death
human
howev
limit
data
regard
etiolog
communityacquir
pneumonia
cap
worldwid
china
unknown
may
lead
inappropri
antimicrobi
therapi
emerg
drugresist
bacteria
sinc
influenza
viru
first
isol
ferret
pneumonia
patient
smith
viral
etiolog
pneumonia
attract
attent
recent
abil
detect
viral
pathogen
dramat
improv
introduct
highli
sensit
nucleic
amplif
test
nat
addit
nat
superior
detect
virus
difficult
grow
cell
cultur
human
rhinoviru
hrv
human
coronavirus
hcov
new
emerg
pathogen
human
metapneumoviru
hmpv
human
bocaviru
hbov
recent
epidemiolog
survey
etiolog
cap
show
respiratori
virus
account
case
howev
real
role
viru
pneumonia
studi
still
controversi
may
partial
due
poor
sensit
viral
test
assay
except
nat
howev
difficult
confirm
pathogen
viru
test
nat
thu
clinic
featur
specif
viral
pneumonia
well
describ
combin
improv
sensit
specif
viral
test
assay
comprehens
design
studi
valuabl
inform
avail
moreov
limit
inform
concern
preval
clinic
featur
viral
pneumonia
guidelin
diagnosi
treatment
cap
provid
much
recommend
assess
manag
viral
cap
order
better
understand
real
role
respiratori
viru
pneumonia
better
manag
patient
conduct
prospect
observ
studi
reveal
viral
etiolog
adult
cap
guangzhou
compar
etiolog
patient
diagnos
influenza
like
ill
ili
volunt
control
april
decemb
consecut
adult
patient
admit
first
affili
hospit
guangzhou
medic
univers
diagnos
cap
within
day
onset
studi
sampl
throat
swab
enrol
pair
sera
least
two
week
interv
cap
defin
presenc
new
infiltr
chest
radiograph
togeth
new
cough
sputum
chang
respiratori
symptom
fever
sign
consolid
lung
rale
leukocytosi
l
leucopenia
l
altern
diagnosi
respons
new
infiltr
followup
exclus
criteria
immunosuppress
eg
human
immunodefici
viru
infect
previou
organ
transplant
immunosuppress
therapi
defin
daili
dose
mg
prednisolon
equival
week
dose
immunosuppress
combin
regimen
includ
azathioprin
cyclosporin
andor
cyclophosphamid
treat
cancer
lung
abscess
aspir
pneumonia
tuberculosi
pregnant
women
patient
releas
hospit
within
day
nt
signatur
consent
exclud
addit
ili
patient
enrol
defin
acut
ill
within
day
fever
two
constitut
symptom
chill
headach
myalgia
fatigu
one
respiratori
symptom
cough
sore
throat
coryza
without
evid
pneumonia
throat
swab
sampl
taken
enrol
pair
sera
taken
two
week
interv
pneumonia
patient
ili
patient
follow
via
telephon
interview
day
data
record
train
doctor
blind
result
viral
detect
moreov
volunt
control
without
clue
acut
ill
within
one
month
also
enrol
sampl
throat
swab
studi
approv
ethic
committe
first
affili
hospit
guangzhou
medic
univers
inform
consent
obtain
subject
pair
sera
routin
perform
hemagglutin
inhibit
assay
detect
season
influenza
viru
type
b
flu
b
pandem
influenza
viru
indirect
immunofluoresc
euroimmun
german
detect
parainfluenza
viru
type
adenoviru
adv
respiratori
syncyti
viru
rsv
fourfold
greater
increas
iggtitr
defin
posit
swab
sampl
process
studi
virus
mention
isol
virus
shellvial
cell
cultur
system
exclud
detect
nucleic
acid
revers
transcript
polymeras
chain
reaction
rtpcr
assay
exclud
swab
sampl
also
test
hrv
hcov
hmpv
hbov
taqman
realtim
rtpcr
rrtpcr
accord
manufactur
protocol
guangzhou
huyansuo
medic
technolog
co
ltd
china
viral
etiolog
consid
definit
least
one
test
posit
statist
softwar
spss
spss
chicago
il
usa
employ
statist
analysi
quantit
data
present
median
interquartil
rang
iqr
compar
nonparametr
kruskalw
test
categor
variabl
report
frequenc
percentag
compar
use
fisher
exact
chisquar
test
logist
regress
analysi
appli
test
whether
certain
clinic
featur
admiss
associ
specif
viru
infect
presenc
absenc
specif
viru
infect
analys
variabl
includ
age
year
sex
current
smoke
statu
sick
contact
febril
patient
number
comorbid
presenc
fever
myalgia
headach
fatigu
dri
cough
coryza
sore
throat
hemoptysi
chest
tight
pain
dyspnea
presenc
neutrophilia
defin
l
leukocytosi
defin
l
lymphopenia
defin
l
logist
regress
analysi
also
appli
test
whether
demograph
featur
specif
viru
infect
associ
sever
diseas
defin
score
equal
greater
admiss
five
risk
factor
includ
confus
new
onset
blood
urea
nitrogen
greater
mmoll
respiratori
rate
breath
per
minut
greater
systol
blood
pressur
less
mmhg
diastol
blood
pressur
less
mmhg
age
older
risk
factor
score
one
point
maximum
score
variabl
includ
model
age
year
sex
current
smoke
statu
sick
contact
febril
patient
number
comorbid
presenc
influenza
infect
presenc
piv
infect
logist
regress
analysi
variabl
p
valu
binari
analysi
enter
multivari
analysi
level
signific
set
overal
individu
enrol
includ
case
cap
case
ili
case
volunt
howev
case
cap
exclud
obstruct
pneumonia
pulmonari
tuberculosi
immunosuppress
patient
sheep
brucellosi
eightynin
patient
least
one
underli
condit
tabl
swab
sampl
avail
patient
volunt
pair
sera
case
cap
patient
ili
patient
viral
etiolog
establish
cap
patient
ili
patient
shown
tabl
volunt
viru
neg
among
virus
cap
patient
virus
detect
shellvial
cell
cultur
system
virus
nat
virus
serolog
survey
respect
figur
sputum
bacteri
cultur
perform
clinic
need
hospit
patient
cap
result
also
record
six
patient
yield
posit
result
tabl
three
six
patient
viru
posit
clinic
featur
sever
ill
cap
patient
summar
tabl
tabl
respect
flu
infect
patient
manifest
hemoptysi
chest
pain
dyspnea
gastrointestin
symptom
also
common
flu
posit
cap
patient
compar
viru
neg
patient
sorethroat
fatigu
common
leukocytosi
neutrophilia
less
common
viral
pneumonia
patient
although
fatigu
neutrophilia
statist
signific
seem
length
hospit
stay
longer
intens
care
requir
mortal
higher
viru
posit
patient
howev
statist
signific
tabl
show
signific
featur
associ
viral
pneumonia
sever
diseas
multivari
analysi
viral
pneumonia
model
leukocytosi
neg
correl
viru
infect
myalgia
includ
model
pneumonia
associ
influenza
infect
model
influenza
infect
found
independ
associ
sever
diseas
score
p
odd
ratio
confid
interv
ci
cap
patient
receiv
antibiot
howev
patient
prescrib
antivir
agent
oseltamivir
zanamivir
clinician
seven
patient
two
viru
posit
receiv
short
cours
intraven
ribavirin
admiss
hospit
one
infect
patient
receiv
oral
oseltamivir
hospit
hospit
final
five
cap
patient
recov
one
month
observ
clinic
cours
four
cap
patient
one
flu
b
posit
one
posit
none
receiv
antivir
drug
went
deterior
deni
go
hospit
stay
die
within
day
hospit
one
copd
patient
diagnos
season
influenza
pneumonia
develop
respiratori
failur
deni
invas
ventil
icu
admiss
ultim
die
three
methodolog
aspect
includ
full
set
viral
test
appli
immunocompet
patient
enrol
two
control
group
made
studi
differ
previou
publish
data
base
methodolog
design
final
found
viru
detect
pneumonia
bystand
pathogen
respiratori
viru
account
onethird
pathogen
cap
henc
common
caus
cap
view
high
preval
viral
cap
urgent
need
consid
routin
laboratori
detect
hospit
cap
patient
adequ
diagnosi
respiratori
virus
addit
consid
posit
correl
influenza
infect
sever
diseas
recommend
test
influenza
viru
routin
sever
individu
especi
activ
period
influenza
activ
viru
pneumonia
may
bystand
pathogen
johnston
de
roux
report
though
aetiolog
nonimmunocompromis
cap
patient
report
real
role
viru
determin
whether
sampl
obtain
upper
respiratori
tract
realli
mirror
true
situat
occur
lower
respiratori
tract
lung
need
studi
henc
two
control
group
introduc
present
studi
answer
question
one
purpos
enrol
two
control
group
describ
inappar
infect
volunt
individu
without
clue
acut
respiratori
ill
within
one
month
higher
rate
viral
infect
ili
patient
anoth
question
extrem
sensit
nat
thought
due
falseposit
previous
volunt
control
studi
turn
viru
neg
expect
comparison
posit
rate
viru
two
control
group
cap
patient
studi
reveal
fals
posit
nat
appear
studi
second
ili
pneumonia
patient
seroconvers
igg
happen
viral
posit
patient
similarli
report
gencay
seroconvers
igg
found
patient
diagnos
lower
respiratori
tract
viral
infect
henc
even
fourfold
elev
viru
specif
antibodi
titer
appear
posit
result
nat
deem
pathogen
current
pneumonia
similar
jen
find
posit
result
viru
nat
cap
consid
pathogen
studi
viral
cap
common
report
worldwid
specul
may
directli
manifest
real
incid
viral
infect
note
data
show
number
unless
otherwis
specifi
leukocytosi
defin
leukocyt
count
l
neutrophilia
defin
neutrophil
count
l
lymphopenia
defin
lymphocyt
count
l
data
avail
patient
comparison
made
viru
posit
patient
viru
neg
patient
nonparametr
kruskalw
test
quantit
characterist
fisher
exact
chisquar
test
categor
variabl
respect
na
data
avail
esr
erythrocyt
sediment
rate
gastrointestin
symptom
includ
nausea
vomit
diarrhea
abdomin
pain
abdomin
distent
note
data
show
number
unless
otherwis
specifi
comparison
made
viru
posit
patient
viru
neg
patient
nonparametr
kruskalw
test
quantit
characterist
fisher
exact
chisquar
test
categor
variabl
respect
patient
deni
hospit
treat
outpati
clinic
emerg
depart
icu
intens
care
unit
cap
local
guangzhou
southern
china
base
methodolog
aspect
mention
howev
influenza
viru
account
twothird
viral
pathogen
cap
studi
henc
higher
preval
viral
cap
might
partial
influenc
pandem
addit
comprehens
viral
test
method
viral
pathogen
improv
yield
viru
also
contribut
higher
proport
viral
pneumonia
cohort
flu
common
viru
cap
viral
pattern
similar
local
influenza
activ
similarli
influenza
viru
shown
predomin
viral
pathogen
cap
spain
patient
acut
exacerb
copd
concomit
pneumonia
hongkong
new
zealand
rhinoviru
commonli
identifi
pathogen
follow
influenza
viru
rsv
differ
preval
specif
viru
infect
among
studi
may
relat
divers
geograph
climat
activ
viru
pandem
commun
local
test
assay
appli
viral
pattern
studi
etc
likewis
clinic
featur
vari
among
studi
jen
new
zealand
report
presenc
myalgia
associ
pneumonia
caus
respiratori
viru
influenza
pneumonia
presenc
chest
pain
leukocytosi
found
far
less
common
patient
viral
infect
bacteri
infect
similar
studi
leukocytosi
less
common
viru
infect
patient
compar
viral
neg
patient
roux
demonstr
chronic
heart
failur
absenc
expector
associ
pure
viral
pneumonia
compar
pneumococc
cap
howev
although
sever
variabl
associ
type
pathogen
clinic
characterist
unabl
reliabl
distinguish
viral
pneumonia
viral
neg
pneumonia
bacteria
pneumonia
differ
clinic
insignific
unless
combin
detect
virus
note
differ
identifi
clinic
characterist
among
studi
may
also
relat
divers
geograph
cultur
healthcar
environ
though
confirm
major
viral
pneumonia
patient
studi
recov
ill
without
aid
antivir
agent
similar
clinic
cours
upper
respiratori
tract
viral
infect
viral
pneumonia
seem
selflimit
ill
howev
one
influenza
pneumonia
patient
studi
die
worsen
comorbid
also
clinic
cours
two
patient
viral
pneumonia
went
deterior
die
discharg
hospit
howev
ill
viru
posit
patient
similar
viru
neg
patient
length
hospit
stay
intens
care
requir
mortal
henc
one
puzzl
question
remain
among
viral
pneumonia
patient
need
treat
antivir
agent
influenza
effect
treat
neuraminidas
inhibitor
obvious
consid
high
preval
viral
cap
guangzhou
influenza
infect
independ
variabl
sever
diseas
model
routin
laboratori
detect
taken
hospit
cap
patient
admiss
adequ
diagnosi
respiratori
virus
especi
influenza
viru
sever
individu
may
benefit
antivir
treatment
latter
conduct
earli
stage
anoth
question
patient
viral
communityacquir
pneumonia
especi
without
evid
bacteria
infect
need
treat
antibiot
plenti
evid
shown
viru
infect
predispos
respiratori
tract
superinfect
anoth
pathogen
bacteria
common
howev
benefit
prevent
prescript
antibiot
antibiot
patient
report
lead
occurr
antibiot
resist
clinic
relev
bacteria
studi
three
pneumonia
patient
viru
bacteria
coinfect
treat
antivir
drug
aid
antibiot
recov
ill
enough
inform
illustr
real
role
antibiot
treatment
viral
pneumonia
studi
yet
henc
randomis
placebocontrol
trial
antibiot
treatment
adult
viral
pneumonia
similar
paediatr
need
help
answer
question
still
sever
limit
studi
first
swab
sampl
test
viral
cultur
nat
increas
sampl
type
nasopharyng
aspir
bronchoalveolar
lavag
fluid
sputum
may
improv
yield
viru
although
multipl
method
appli
undoubtedli
still
underestim
preval
respiratori
viru
infect
type
pathogen
henc
viral
neg
patient
could
rule
virus
infect
outsid
scope
test
studi
second
bacteria
atyp
pathogen
studi
henc
comparison
clinic
characterist
made
viru
posit
patient
viru
neg
patient
final
three
season
cover
studi
longer
time
last
two
year
patient
enrol
may
provid
us
use
inform
howev
work
ongo
describ
epidemiolog
clinic
characterist
viral
cap
deepli
respiratori
viru
bystand
pathogen
pneumonia
common
caus
cap
recommend
test
influenza
viru
routin
sever
individu
especi
activ
period
influenza
activ
